Schizophrenia is a chronic mental disorder affecting millions worldwide. It has no known cure. Current pharmaceutical treatments have shown efficacy in only one of the three symptom clusters of schizophrenia, providing little or no benefit in the other two. Furthermore, the current standard-of-care drugs, known as atypical antipsychotics, carry risks of severe side effects affecting multiple body systems. Most patients opt to discontinue drug therapy within two years of initiation due to lack of efficacy and/or preponderance of adverse effects. Previous findings have shown that chronic usage of atypical antipsychotics causes a 5-HT2A-dependent upregulation of histone deacetylase 2 (HDAC2), which in turn leads to downregulation of metabotropic glutamate receptor 2 (mGluR2), a G protein-coupled receptor with an important role in synaptic plasticity. The present study aims to characterize the extent to which this downregulation leads to specific functional outcomes, and in doing so, may help identify new targets for more effective treatment of schizophrenia.
| Identifer | oai:union.ndltd.org:vcu.edu/oai:scholarscompass.vcu.edu:etd-6550 |
| Date | 01 January 2018 |
| Creators | Cuddy, Travis M |
| Publisher | VCU Scholars Compass |
| Source Sets | Virginia Commonwealth University |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | Theses and Dissertations |
| Rights | © Travis M. Cuddy |
Page generated in 0.0017 seconds